Subclinical signs in LRRK2 mutation carriers

被引:24
|
作者
Johansen, Krisztina K. [1 ,2 ]
White, Linda R. [1 ,2 ]
Farrer, Matthew J. [3 ]
Aasly, Jan O. [1 ,2 ]
机构
[1] St Olavs Univ Hosp, Dept Neurol, N-7006 Trondheim, Norway
[2] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
[3] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
关键词
Parkinson's disease; G2019S; N1437H; Premotor; Hyposmia; LRRK2-ASSOCIATED PARKINSONS-DISEASE; DOPAMINERGIC DYSFUNCTION; CLINICAL-DIAGNOSIS; PROGRESSION; ACCURACY; FEATURES; PHASE; RISK;
D O I
10.1016/j.parkreldis.2011.04.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Several non-motor features have been reported to precede the motor signs of Parkinson's disease (PD) by several years. However, the time of onset of non-motor and motor symptoms is still debated. Healthy individuals carrying a PD-related mutation are candidates for studying the earliest disease signs. Objectives: To describe clinically healthy family members of PD patients carrying a LRRK2 mutation (LRRK2-PD). Methods:A total of 47 family members of LRRK2-PD patients were included in the present study and were screened for the p.G2019S and p.N1437H substitutions in the LRRK2 gene. A standardized case report form was filled out in each case, including general medical evaluation, neurological examination with UPDRS, an olfaction test, mood, sleep and cognitive questionnaires. Results: Thirty-two study participants were positive, and 15 were negative for a LRRK2 mutation. Higher UPDRS motor scores, more frequent reports of urinary problems, and fewer hours of sleep were found in mutation carriers compared to non-carriers. The mutation carriers with UPDRS >= 8 were all aged over 50 years, had shorter overall sleeping hours, more frequent urinary and constipation problems, higher mood scores and body mass index. Deterioration of olfaction was not detected in either group. Conclusion: Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss. Longitudinal studies will determine whether these changes precede alterations detectable by neuroimaging. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:528 / 532
页数:5
相关论文
共 50 条
  • [41] Computational analysis of the LRRK2 interactome
    Manzoni, Claudia
    Denny, Paul
    Lovering, Ruth C.
    Lewis, Patrick A.
    PEERJ, 2015, 3
  • [42] Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers
    Garrido, Alicia
    Perez-Sisques, Leticia
    Simonet, Cristina
    Campoy-Campos, Genis
    Solana-Balaguer, Julia
    Martin-Flores, Nuria
    Fernandez, Manel
    Soto, Marta
    Obiang, Donina
    Camara, Ana
    Valldeoriola, Francesc
    Munoz, Esteban
    Compta, Yaroslau
    Perez-Navarro, Esther
    Alberch, Jordi
    Tolosa, Eduardo
    Marti, Maria-Jose
    Ezquerra, Mario
    Malagelada, Cristina
    Fernandez-Santiago, Ruben
    ANNALS OF NEUROLOGY, 2022, 92 (05) : 888 - 894
  • [43] A case of restless leg syndrome in a family with LRRK2 gene mutation
    De Rosa, Anna
    Guacci, Anna
    Peluso, Silvio
    Del Gaudio, Luigi
    Massarelli, Marco
    Barbato, Stefano
    Criscuolo, Chiara
    De Michele, Giuseppe
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2013, 123 (04) : 283 - 285
  • [44] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
    T. De Wit
    V. Baekelandt
    E. Lobbestael
    Molecular Neurobiology, 2019, 56 : 5273 - 5286
  • [45] Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation
    Mutez, Eugenie
    Larvor, Lydie
    Lepretre, Frederic
    Mouroux, Vincent
    Hamalek, Dorota
    Kerckaert, Jean-Pierre
    Perez-Tur, Jordi
    Waucquier, Nawal
    Vanbesien-Mailliot, Christel
    Duflot, Aurelie
    Devos, David
    Defebvre, Luc
    Kreisler, Alexandre
    Frigard, Bernard
    Destee, Alain
    Chartier-Harlin, Marie-Christine
    NEUROBIOLOGY OF AGING, 2011, 32 (10) : 1839 - 1848
  • [46] A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers
    Bregman, Noa
    Thaler, Avner
    Mirelman, Anat
    Helmich, Rick C.
    Gurevich, Tanya
    Orr-Urtreger, Avi
    Marder, Karen
    Bressman, Susan
    Bloem, Bastiaan R.
    Giladi, Nir
    BRAIN STRUCTURE & FUNCTION, 2017, 222 (03) : 1207 - 1218
  • [47] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
    De Wit, T.
    Baekelandt, V.
    Lobbestael, E.
    MOLECULAR NEUROBIOLOGY, 2019, 56 (08) : 5273 - 5286
  • [48] Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years' follow-up
    Sanchez-Rodriguez, Antonio
    Martinez-Rodriguez, Isabel
    Sanchez-Juan, Pascual
    Sierra, Maria
    Gonzalez-Aramburu, Isabel
    Rivera-Sanchez, Maria
    Andres-Pacheco, Javier
    Gutierrez-Gonzalez, Angela
    Garcia-Hernandez, Adrian
    Madera, Jorge
    Delgado-Alvarado, Manuel
    Infante, Jon
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (12) : 4204 - 4208
  • [49] Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation
    Thaler, Avner
    Gonen, Tal
    Mirelman, Anat
    Helmich, Rick C.
    Gurevich, Tanya
    Orr-Urtreger, Avi
    Bloem, Bastiaan R.
    Giladi, Nir
    Hendler, Talma
    BRAIN IMAGING AND BEHAVIOR, 2019, 13 (04) : 1009 - 1020
  • [50] Higher Frequency of Certain Cancers in LRRK2 G2019S Mutation Carriers With Parkinson Disease A Pooled Analysis
    Agalliu, Ilir
    San Luciano, Marta
    Mirelman, Anat
    Giladi, Nir
    Waro, Bjorg
    Aasly, Jan
    Inzelberg, Rivka
    Hassin-Baer, Sharon
    Friedman, Eitan
    Ruiz-Martinez, Javier
    Felix Marti-Masso, Jose
    Orr-Urtreger, Avi
    Bressman, Susan
    Saunders-Pullman, Rachel
    JAMA NEUROLOGY, 2015, 72 (01) : 58 - 65